Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1)
NCT01025596
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
COMPLETED
Status
10
Enrollment
INDUSTRY
Sponsor class
Conditions
Hepatitis C
Interventions
DRUG:
Interleukin-7
Sponsor
Cytheris SA